tiprankstipranks
Advertisement
Advertisement
BridgeBio Oncology price target lowered to $18 from $20 at Morgan Stanley
PremiumThe FlyBridgeBio Oncology price target lowered to $18 from $20 at Morgan Stanley
3M ago
Reaffirming Buy on BridgeBio Oncology: Differentiated KRASG12C Profile, Strong Early Efficacy, and Broad Keytruda Combination Potential
Premium
Ratings
Reaffirming Buy on BridgeBio Oncology: Differentiated KRASG12C Profile, Strong Early Efficacy, and Broad Keytruda Combination Potential
3M ago
BridgeBio Oncology reports promising RAS and PI3Kα data
Premium
Company Announcements
BridgeBio Oncology reports promising RAS and PI3Kα data
3M ago
BridgeBio Oncology price target lowered to $22 from $23 at Oppenheimer
PremiumThe FlyBridgeBio Oncology price target lowered to $22 from $23 at Oppenheimer
5M ago
BridgeBio Oncology reports Q3 EPS ($1.03), consensus (34c)
Premium
The Fly
BridgeBio Oncology reports Q3 EPS ($1.03), consensus (34c)
5M ago
BridgeBio Oncology’s Promising Preclinical Data and Strategic Advancements Justify Buy Rating
Premium
Ratings
BridgeBio Oncology’s Promising Preclinical Data and Strategic Advancements Justify Buy Rating
5M ago
BridgeBio Oncology initiated with an Outperform at Oppenheimer
PremiumThe FlyBridgeBio Oncology initiated with an Outperform at Oppenheimer
7M ago
BridgeBio Oncology initiated with an Overweight at Piper Sandler
Premium
The Fly
BridgeBio Oncology initiated with an Overweight at Piper Sandler
8M ago
BridgeBio Oncology initiated with an Overweight at Piper Sandler
Premium
The Fly
BridgeBio Oncology initiated with an Overweight at Piper Sandler
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100